Phosphodiesterase 4 Inhibitor, Roflumilast, and the Effects of Inhibition in Severe Asthma
Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
This study evaluates the effects of roflumilast on restoring response β2 adrenoreceptor
agonists in low T2, obese asthmatics. One group of participants will receive roflumilast for
3 months, while the other will receive a placebo.